Cargando…
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
INTRODUCTION: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) inhibitors among patients with NSCLC. METHODS: We r...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474252/ https://www.ncbi.nlm.nih.gov/pubmed/34589927 http://dx.doi.org/10.1016/j.jtocrr.2020.100020 |
_version_ | 1784575171444604928 |
---|---|
author | Miyawaki, Taichi Naito, Tateaki Kodama, Akihro Nishioka, Naoya Miyawaki, Eriko Mamesaya, Nobuaki Kawamura, Takahisa Kobayashi, Haruki Omori, Shota Wakuda, Kazushige Ono, Akira Kenmotsu, Hirotsugu Murakami, Haruyasu Notsu, Akifumi Mori, Keita Harada, Hideyuki Endo, Masahiro Takahashi, Kazuhisa Takahashi, Toshiaki |
author_facet | Miyawaki, Taichi Naito, Tateaki Kodama, Akihro Nishioka, Naoya Miyawaki, Eriko Mamesaya, Nobuaki Kawamura, Takahisa Kobayashi, Haruki Omori, Shota Wakuda, Kazushige Ono, Akira Kenmotsu, Hirotsugu Murakami, Haruyasu Notsu, Akifumi Mori, Keita Harada, Hideyuki Endo, Masahiro Takahashi, Kazuhisa Takahashi, Toshiaki |
author_sort | Miyawaki, Taichi |
collection | PubMed |
description | INTRODUCTION: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) inhibitors among patients with NSCLC. METHODS: We retrospectively reviewed medical records of patients with advanced NSCLC who received PD-1 or PD-L1 inhibitor monotherapy from May 2016 to December 2018. We defined cancer cachexia as unintentional weight loss greater than 5% over 6 months and high PD-L1 as greater than 50% expression on tumor cells. We evaluated the objective response rates (ORRs) and progression-free survival (PFS). RESULTS: Among 108 patients, 52 had cancer cachexia. Patients with cachexia had a lower ORR (15% versus 57%, p < 0.001) and shorter PFS (2.3 mo versus 12.0 mo, p < 0.001) than those without cachexia. Patients with low PD-L1 expression had a lower ORR (14% versus 53%, p < 0.001) and shorter PFS (2.8 mo versus 10.8 mo, p = 0.002) than those with high PD-L1 expression. Multivariate analysis revealed cancer cachexia and low PD-L1 expression as independent negative predictors of PFS. Among patients with cachexia, there was no significant difference in the ORR (p = 0.514) or PFS (p = 0.992) on the basis of PD-L1 expression. CONCLUSIONS: Our findings indicate that cancer cachexia might be a negative predictor of the efficacy of PD-1 or PD-L1 inhibitors and reduce the impact of PD-L1 expression on the effect of PD-1 or PD-L1 inhibitors in patients with advanced NSCLC. Further clinical and basic studies are needed. |
format | Online Article Text |
id | pubmed-8474252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84742522021-09-28 Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC Miyawaki, Taichi Naito, Tateaki Kodama, Akihro Nishioka, Naoya Miyawaki, Eriko Mamesaya, Nobuaki Kawamura, Takahisa Kobayashi, Haruki Omori, Shota Wakuda, Kazushige Ono, Akira Kenmotsu, Hirotsugu Murakami, Haruyasu Notsu, Akifumi Mori, Keita Harada, Hideyuki Endo, Masahiro Takahashi, Kazuhisa Takahashi, Toshiaki JTO Clin Res Rep Original Article INTRODUCTION: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) inhibitors among patients with NSCLC. METHODS: We retrospectively reviewed medical records of patients with advanced NSCLC who received PD-1 or PD-L1 inhibitor monotherapy from May 2016 to December 2018. We defined cancer cachexia as unintentional weight loss greater than 5% over 6 months and high PD-L1 as greater than 50% expression on tumor cells. We evaluated the objective response rates (ORRs) and progression-free survival (PFS). RESULTS: Among 108 patients, 52 had cancer cachexia. Patients with cachexia had a lower ORR (15% versus 57%, p < 0.001) and shorter PFS (2.3 mo versus 12.0 mo, p < 0.001) than those without cachexia. Patients with low PD-L1 expression had a lower ORR (14% versus 53%, p < 0.001) and shorter PFS (2.8 mo versus 10.8 mo, p = 0.002) than those with high PD-L1 expression. Multivariate analysis revealed cancer cachexia and low PD-L1 expression as independent negative predictors of PFS. Among patients with cachexia, there was no significant difference in the ORR (p = 0.514) or PFS (p = 0.992) on the basis of PD-L1 expression. CONCLUSIONS: Our findings indicate that cancer cachexia might be a negative predictor of the efficacy of PD-1 or PD-L1 inhibitors and reduce the impact of PD-L1 expression on the effect of PD-1 or PD-L1 inhibitors in patients with advanced NSCLC. Further clinical and basic studies are needed. Elsevier 2020-03-04 /pmc/articles/PMC8474252/ /pubmed/34589927 http://dx.doi.org/10.1016/j.jtocrr.2020.100020 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Miyawaki, Taichi Naito, Tateaki Kodama, Akihro Nishioka, Naoya Miyawaki, Eriko Mamesaya, Nobuaki Kawamura, Takahisa Kobayashi, Haruki Omori, Shota Wakuda, Kazushige Ono, Akira Kenmotsu, Hirotsugu Murakami, Haruyasu Notsu, Akifumi Mori, Keita Harada, Hideyuki Endo, Masahiro Takahashi, Kazuhisa Takahashi, Toshiaki Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title_full | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title_fullStr | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title_full_unstemmed | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title_short | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
title_sort | desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced nsclc |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474252/ https://www.ncbi.nlm.nih.gov/pubmed/34589927 http://dx.doi.org/10.1016/j.jtocrr.2020.100020 |
work_keys_str_mv | AT miyawakitaichi desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT naitotateaki desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT kodamaakihro desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT nishiokanaoya desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT miyawakieriko desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT mamesayanobuaki desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT kawamuratakahisa desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT kobayashiharuki desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT omorishota desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT wakudakazushige desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT onoakira desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT kenmotsuhirotsugu desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT murakamiharuyasu desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT notsuakifumi desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT morikeita desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT haradahideyuki desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT endomasahiro desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT takahashikazuhisa desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc AT takahashitoshiaki desensitizingeffectofcancercachexiaonimmunecheckpointinhibitorsinpatientswithadvancednsclc |